Collaboration to Accelerate NGS and Immunology Diagnostic Tools Announced

Mayo Clinic, a nonprofit organisation committed to innovation in clinical practice, education and research, and Thermo Fisher Scientific have joined forces to bring innovative solutions to patients by accelerating clinical validation, and commercialisation of selected next-generation sequencing (NGS), mass spectrometry and immunology diagnostic tools. The Advanced Diagnostics Laboratory in One Discovery Square, which is part of the Destination Medical Center initiative, will be the home for this collaboration.

"By pairing cutting-edge, innovative technologies with world-class clinical and diagnostic testing knowledge, this collaboration will ensure that the promising innovations are both clinically relevant and accessible globally," said William Morice II, MD, PhD, chair of Mayo Clinic’s Department of Laboratory Medicine and Pathology and president of Mayo Clinic Laboratories. 

The Mayo Clinic and Thermo Fisher teams are working closely to identify candidate solutions for clinical validation and global commercialisation as part of the collaboration. 

"We are excited to join forces with Mayo Clinic to accelerate access to precise and affordable diagnostics for patients across the globe," said Gianluca Pettiti, Senior Vice President and President, Specialty Diagnostics at Thermo Fisher. "The collaborative effort will leverage NGS, mass spectrometry and immunology technologies to advance haematology, oncology, allergy and autoimmunity diagnostics." 

Mayo Clinic and Thermo Fisher are evaluating diagnostic solutions for multiple applications, including myeloid leukaemia and therapeutic drug monitoring panels to deliver access to more precise and personalised insights for patient care.